Sunarium Sunitinib Malate Capsules 25 mg is a prescription oral oncology medicine identified as containing Sunitinib Malate, with a stated strength of 25 mg per capsule.

Sunitinib is a multikinase inhibitor used as targeted anticancer therapy. It acts on several receptor tyrosine kinases involved in tumor-cell signaling, cancer growth and the formation of new blood vessels.

Sunitinib is an established treatment option in selected cases of advanced renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) and progressive pancreatic neuroendocrine tumors (pNET).

Treatment suitability depends on the diagnosis, disease stage, previous therapy, clinical condition and applicable regulatory approvals.

The 25 mg capsule strength does not represent a universal patient dose. The exact salt equivalence, manufacturer, packaging, storage conditions and approved indications of Sunarium must be verified from the approved Indian product documentation.

Marketed by Essentials Emporium Enterprises, Sunarium is listed within the oncology pharmaceutical category for hospitals, cancer treatment centres and authorized pharmaceutical buyers.

Key Product Features